Advertisement

Zytostatische Chemotherapie der Weichteilsarkome im Erwachsenenalter — wann ist sie indiziert?

  • J. H. Hartlapp
Conference paper

Zusammenfassung

Weichteilsarkome bei Erwachsenen zählen zu den seltenen Tumoren. Während sie bei Kindern und Jugendlichen bis zu 15 Jahren 6,5% aller bösartigen Geschwülste ausmachen, ist ihre zahlenmäßige Bedeutung mit nur 0,7% im Erwachsenenalter gering. Die Inzidenz beträgt 1:100 000 Erwachsenen pro Jahr.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Antman KM, Montella D, Rosenbaum Ch, Schwen M (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 68: 499–504Google Scholar
  2. Benjamin RS, Terjanian TO, Fenoglio CJ, Barkley HT, Evans HL, Murphy, Martin RG (1987) The importance of combination chemotherapy for adjuvant treatment of high-risk patients with soft tissue sarcomas of the extremities. In: Adjuvant Therapy of Cancer V. Grune & Stratton pp 735–744Google Scholar
  3. Blackledge G, Verweij J, Fuchs R, Keizer J, Rodenhuis C, Rankin E, Kerbrat P, Oosterom AT van, Sylvester R, Thomas D, Rouesse J (1989) A phase II study of M-azidopyrimethamine ethane sulphonate (MZPES) in advanced recurrent soft tissue sarcoma: an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 25: 1891–1893CrossRefGoogle Scholar
  4. Borden EC, Amato DA, Rosenbaum Ch et al. (1987) Randomized comparison of three adriamycin regiments for metastatic soft tissue sarcomas. J Clin Oncol 5: 840–850PubMedGoogle Scholar
  5. Bowden L, Booher RJ (1958) The principle and technique of resection of soft parts of sarcoma. Surgery 44: 963–977PubMedGoogle Scholar
  6. Bramwell VHC, Mouridsen H, Santoro A, Blackledge G, Somers R, Verweij J, Dombernowsky P, Onsrud M, Thomas D. Sylvester R, Oosterom AT van (1987) Cyclophos-phamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311–321Google Scholar
  7. Brühl P, Günther U, Hoefer-Janker H, Hüls W, Scheef W, Vahlensieck W (1976) Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours. Int J Clin Pharmacol 14: 29–39Google Scholar
  8. Budd GT, Metch B, Balcerzak SP, Flechtcher WS, Baker LH, Mortimer JE (1990) High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 65: 866–869PubMedCrossRefGoogle Scholar
  9. Buesa JM, Mouridsen HT, Oosterom AT van, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R (1991) High-dose DTIC in advanced soft tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 2: 307–309Google Scholar
  10. Dombernowsky P, Buesa J, Pinedo HM, Santoro A, Mouridsen HT, Somers R, Bramwell V, Onsrud M, Rouesse J, Thomas D, Sylvester R (1987) VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23: 579–580PubMedCrossRefGoogle Scholar
  11. Enneking WF, Spanier SS, Malawer MM (1981) The effect of the anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh. Cancer 47: 1005–1022PubMedCrossRefGoogle Scholar
  12. Gherlinzoni F, Bacci G, Picci P, Lapanna R, Calderoni P, Lorenzi EG, Bernini M, Emiliani E, Barbieri E, Mormand A, Campanacci M (1986) A randomized trial for the treatment of high-grade soft tissue sarcomas of the extremities. Preliminary observations. J Clin Oncol 4: 552–558Google Scholar
  13. Glabbeke M van, Thomas D, Verweij J, Woll P, Somers R, Santoro A, Buesa J, Haelst U van, Mouridsen H (1991) Prognostic factors of survival and response in patients treated with doxorubicin as first line therapy for advanced soft tissue sarcoma: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study. Proc ECCO-6: 972, 162Google Scholar
  14. Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Sinkovics JG, Rivkin SE, Brownlee R, Frei E (1972) Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30: 1632–1638PubMedCrossRefGoogle Scholar
  15. Gottlieb JA, Baker LH, O’Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez VT, Blumenschein GR, Saiki JH, Coltman C, Burgess NA, Sullivan P, Thipgen T, Bottemley R, Balcerzak S, Moon TE (1975) Adriamycin (NSC-123127), used alone and in combination for soft tissue and bone sarcomas. Cancer Chemother Rep 6: 271–282Google Scholar
  16. Gottlieb JA, Benjamin RS, Baker LH (1976) Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60: 199–203PubMedGoogle Scholar
  17. Klein HO (1983) High-dose ifosfamide and mesna as continuous infusion one five days a phase Uli trial. Cancer Treat Rev 10 [Suppl A]: 167–173PubMedCrossRefGoogle Scholar
  18. Leibel SA, Tranbaugh RF, Wara WM, Beckstead JH, Bovill EG, Phillips TL (1982) Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer 50: 1076–1083PubMedCrossRefGoogle Scholar
  19. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT (1981) Conservative surgery and postoperative radiotherapie in 300 adults with soft tissue sarcomas. Cancer 47: 2391–2397PubMedCrossRefGoogle Scholar
  20. Mazanet R, Antman KH (1991) Sarcomas of soft tissue and bone. Cancer 68: 463–473 Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, Oosterom AT van, Buesa J, Pinedo HM, Thomas D, Sylvester R (1987) Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23: 1477–1483Google Scholar
  21. O’Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1–8PubMedCrossRefGoogle Scholar
  22. Pinedo HM, Bramwell VHC, Mouridsen HT, Somers R, Vendrik CPJ, Santoro A, Buesa J, Wagener Th, Oosterom AT van, Unnik JAM van et al. (1984) CYVADIC in advanced soft tissue sarcoma: a randomized study comparing two schedules. Cancer 53: 1825–1832PubMedCrossRefGoogle Scholar
  23. Ravaud A, Bui NB, Coindre JM, Kantor G, Stöckle E, Lagarde P, Becouarn Y, Chauvergne J, Bonichon F, Maree D (1990) Adjuvant chemotherapy with CYVADIC in high risk soft tissue sarcoma: a randomized prospective trial. In: Salmon SE (ed) Adjuvant Therapy of Cancer V I. WB Saunders Company, PhiladelphiaGoogle Scholar
  24. Rosenberg SA, Tepper J, Gladstein E, Costa J, Young R, Baker A, Brennan MF, Demoss EV, Seipp C, Sindelar WF, Sugerbaker P, Wesley R (1983) Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 52: 424–434PubMedCrossRefGoogle Scholar
  25. Rouessé JG, Oosterom AT van, Capellaere P, Kerbrat P, Groeningen CJ van, Thomas D, Benshahar D (1987) Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma: a trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group. Eur J Cancer Clin Oncol 23: 1413–1414PubMedCrossRefGoogle Scholar
  26. Russel WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG, Meissner W, Miller WT, Schmitz RL, Suit HD (1977) A clinical and pathological staging system for soft tissue sarcomas. Cancer 40: 1562–1570CrossRefGoogle Scholar
  27. Santoro A, Rouesse J, Steward W, Mouridsen H, Verweij J, Somers R, Blackledge G, Buesa J, Sayer H, Tursz T, Thomas D, Sylvester R, Ooesterom AT van (1990) A randomized EORTC study in advanced soft tissue sarcomas (STS): ADM vs. ADM+IFX vs. CYVADIC. Proc ASCO 9: 309Google Scholar
  28. Schnitker J, Brock N, Burkert H, Fichtner E (1976) Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. Arzneim Forsch (Drug Res.) 26, Nr. 10: 1783–1793Google Scholar
  29. Schoenfeld DA, Rosenbaum Ch, Horton J, Wolter JM, Falkson G, DeConti RC (1982) A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50: 2757–2762PubMedCrossRefGoogle Scholar
  30. Sordillo PP, Magill GB, Brenner J, Cheng EW, Dosik M, Yagoda A (1987) A phase II evaluation of cisplatin in previously untreated patients with soft tissue sarcomas. Cancer 59: 884–886PubMedCrossRefGoogle Scholar
  31. Steward WP, Mouridson H, Kerbrat P, Somers R, Verweij J, Oosterom AT van, Blackledge G, Thomas D, Sylvester R (1989) Phase II trial of methylene-dimethane sulphonate ( MDMS) in advanced soft tissue sarcomas of the adult. Eur J Cancer 25: 1251–1253Google Scholar
  32. Steward WP, Verweij J, Somers R, Blackledge G, Clavel M, Kerbrat P, Crowther D, Tursz T, Oosterom AT van, Rouesse J, Tueni T, Soedirman M, Thomas D, Glabbeke M van (1991) High dose chemotherapy (ct) with two schedules of recombinant human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in the treatment of advanced adult soft tissue sarcomas (sts). Proc ASCO 10: 349, No 1240Google Scholar
  33. Stuart-Harris RC, Haper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11: 69–72PubMedCrossRefGoogle Scholar
  34. Wiltshaw E, Westbury G, Harmer C, McKinna A, Fischer C (1986) Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol [Suppl 2] 18: 10–12CrossRefGoogle Scholar
  35. Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R,ThigpenT, Burgess MA, Benjamin RS, Bodey GP (1980) Cyclophosphamide, vincristine, adriamycin, and DTIC ( CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64: 93–98Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. H. Hartlapp

There are no affiliations available

Personalised recommendations